Hemocompatibility of Silver Nanoparticles Based on Conjugate of Quaternized Chitosan with Gallic Acid in In Vitro Experiments

• Published in: Bulletin of experimental biology and medicine Vol. 168; no. 4; pp. 507 - 511
• Main Authors: Drozd, N. N., Lunkov, A. P., Il’ina, A. V., Varlamov, V. P.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-02-2020; Springer
• Subjects: Adenosine Triphosphate - pharmacology; Anticoagulants (Medicine); Biomedical and Life Sciences; Biomedicine; Biotechnologies; Blood Coagulation - drug effects; Blood Coagulation Tests; Blood Platelets - cytology; Blood Platelets - drug effects; Cell Biology; Chitosan - chemistry; Erythrocytes - cytology; Erythrocytes - drug effects; Gallic Acid - chemistry; Glycoconjugates - chemistry; Glycoconjugates - pharmacology; Hemolysis - drug effects; Humans; Internal Medicine; Laboratory Medicine; Metal Nanoparticles - chemistry; Nanoparticles; Pathology; Phenols; Platelet Aggregation - drug effects; Primary Cell Culture; Silver; Silver - chemistry; Silver - pharmacology; chitosan; plasma coagulation; silver nanoparticles; erythrocyte hemolysis
• ISSN: 0007-4888; 1573-8221
• DOI: 10.1007/s10517-020-04742-8

We studied hemocompatibility of silver nanoparticles synthesized on the basis of a conjugate of quaternized chitosan with gallic acid (QChit-Gal). For the three variants of silver particles (Nos. 1, 2, and 3), the QChit-Gal:AgNO
3
ratio was 5:1, 5:3, and 1:1, respectively. Anticoagulant activity of all samples of silver nanoparticles was lower than that of the conjugate. Samples of nanoparticles Nos. 1 and 2 in a concentration of 0.0233 mg/ml did not affect plasma clotting time and can be used for intravenous administration. However, their concentration in the blood should not exceed 0.01 mg/ml, because in this concentration they do not affect erythrocyte membrane, do not induce platelet aggregation, and do not affect platelet aggregation induced by ADP.